Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD200R1 monoclonal antibody 23ME-00610

A humanized monoclonal antibody directed against the immune checkpoint cell surface transmembrane glycoprotein CD200 receptor 1 (CD200R1; CD200R; HCRTR2; MOX2R; OX2R; CD200 receptor 1), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-CD200R1 monoclonal antibody 23ME-00610 targets and binds to CD200R1, thereby preventing the interaction of CD200R1 with its ligand CD200, which is highly expressed on certain tumor cell types, and preventing its activity. This inhibits CD200R1-mediated signaling pathways and may re-activate tumor-exhausted T cells and myeloid cells. This may lead to a T-cell mediated anti-tumor immune response and may kill cancer cells. CD200R1 is an inhibitory receptor expressed on T cells and myeloid cells and plays a key role in the maintenance of immune tolerance and immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:23ME 00610
23ME-00610
23ME00610
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search